Lascufloxacin hydrochloride to treat bacterial infection.

Lascufloxacin hydrochloride to treat bacterial infection.
Drugs Today (Barc). 2020 Jun;56(6):365-376
Authors: Thakare R, Singh S, Dasgupta A, Chopra S
Abstract
Lascufloxacin hydrochloride (AM-1977) is a novel 8-methoxy fluoroquinolone antibacterial agent with a unique pharmacophore at the 1st and 7th positions of the quinoline nucleus developed by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). It has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for treatment of respiratory tract and ear, nose and throat infections including community-acquired pneumonia and otorhinolaryngological infections, and shows great promise against fluoroquinolone-resistant strains of major pathogens which infect the respiratory tract. It is suitable for treating infections caused by Staphylococcus, Streptococcus, Pneumococcus, Moraxella (Branhamella) catarrhalis, Klebsiella, Enterobacter, Haemophilus influenzae, Legionella pneumophila, Prevotella and Mycoplasma pneumoniae that are sensitive to this drug.
PMID: 32525135 [PubMed - in process]

Source: Drugs of Today - June 12, 2020 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research